Absci Collaborates with Oracle and AMD to Speed up AI-Led Drug Discovery, Shares Jump

Tiger Newspress
Sep 11

Absci on Thursday announced a collaboration with Oracle Cloud Infrastructure and AMD to accelerate its AI-driven drug discovery efforts.

Absci shares jumped 9.5 in morning trading.

As part of the partnership, the Vancouver, Washington-based biotech will use Oracle’s AI infrastructure and AMD’s hardware for its generative AI Drug Creation Platform.

“This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows,” CEO Sean McClain remarked.

The announcement coincided with the Oracle Health and Life Sciences Summit taking place in Orlando, Florida, from Sept. 9 to 11.

During the event, the tech giant highlighted some of its healthcare-related advancements, including its AI capabilities within the Oracle Fusion Cloud Application, which it said could streamline supply chain operations within the industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10